Skye Bioscience

Skye Bioscience Earnings Yield

The Earnings Yield of Skye Bioscience (SKYE) as of Oct 16, 2026 is -241.02 %. In the previous year, Earnings Yield was -114.50 % — a change of 110.50% (lower).

Earnings Yield

-241.02 %

YoY

110.50%

Last updated:

Earnings Yield of Skye Bioscience is 2025 -241.02 % . Earnings Yield of Skye Bioscience was 2024 -114.50 % . It decreases by 110.50% lower compared to the previous year.

The Skye Bioscience Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-82.72 USD
Jan 1, 2019
4.53 USD
Jan 1, 2020
-28.28 USD
Jan 1, 2021
-36.73 USD
Jan 1, 2022
-83.96 USD
Jan 1, 2023
-162.24 USD
Jan 1, 2024
-114.50 USD
Jan 1, 2025
-241.02 USD
The Skye Bioscience Earnings Yield history
YEAREarnings YieldYoY
-241.02 %+110.50%
-114.50 %-29.43%
-162.24 %+93.23%
-83.96 %+128.60%
-36.73 %+29.89%
-28.28 %-723.67%
4.53 %-105.48%
-82.72 %+520.36%
-13.33 %-2.64%
-13.70 %-34.35%
-20.86 %+77.07%
-11.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skye Bioscience Stock analysis

What does Skye Bioscience do? Skye Bioscience Inc is a biotechnology company headquartered in San Diego, California, with a focus on developing cannabinoid derivatives for therapeutic applications. The company has 11 full-time employees and went public via an IPO on February 24, 2014. Skye Bioscience operates within the health care sector, specifically in the biotechnology industry. Its primary research involves the discovery and development of cannabinoid-based compounds targeting the endocannabinoid system. The company's lead product candidate, SBI-100 OE, is under development for treating glaucoma and ocular hypertension. A first-in-human Phase I clinical trial for SBI-100 OE is currently being conducted in Australia with healthy volunteers to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Additionally, Skye Bioscience is working on SBI-200, which has shown potential in early studies for analgesic, anti-inflammatory, anti-fibrotic, and anti-seizure applications. The company also explores SBI-200's potential for treating various eye conditions, including uveitis, dry eye syndrome, macular degeneration, and diabetic-related eye diseases. Skye Bioscience maintains a website at skyebioscience.com for further information. The company's operations and product development are centered around addressing unmet medical needs through cannabinoid-based therapies. Skye Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Skye Bioscience stock

Earnings Yield of Skye Bioscience is -241.02 % in 2025.

Earnings Yield of Skye Bioscience changed from -114.50 % to -241.02 %, representing a 110.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Skye Bioscience since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Skye Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Skye Bioscience

All Key Metrics — Skye Bioscience